Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Positive phase III fasedienol results propel innovative pherine nasal spray as potential game-changer for social anxiety disorder."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Positive phase III fasedienol results propel innovative pherine nasal spray as potential game-changer for social anxiety disorder."> <meta property="og:title" content="Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope"> <meta name="twitter:description" content="Positive phase III fasedienol results propel innovative pherine nasal spray as potential game-changer for social anxiety disorder."> <meta name="twitter:title" content="Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/discovery-development/resources/nasal-spray-shows-remarkable-efficacy-in-easing-social-anxiety-vistagens-fasedienol-promises-new-hope"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Tom-Industry-Spotlight-Template.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Tom-Industry-Spotlight-Template.jpg"> <meta property="og:url" content="https://oxfordglobal.com/discovery-development/resources/nasal-spray-shows-remarkable-efficacy-in-easing-social-anxiety-vistagens-fasedienol-promises-new-hope"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="discovery-development"> <div class="body-wrapper hs-content-id-177028096592 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/discovery-development" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/discovery-development/events/discovery-development-europe-2025" class="pill center"> <div class="b">Discovery & Development Europe 2025</div> <div class="heading-smallcaps"> 01 - 02 Jul 2025 | Basel, Switzerland </div> </a> <a href="/discovery-development/events/discovery-development-us-2025" class="pill center"> <div class="b">Discovery & Development US 2025</div> <div class="heading-smallcaps"> 02 - 03 Oct 2025 | San Diego, CA </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/discovery-development/online#Controlled%20Release%20Formulations" class="cta" target="_blank"> <h3 class="other-resources">26/06/24 - Controlled Release Formulations</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>We empower scientific decision-makers from the world’s most innovative biopharma organisations to make informed pipeline decisions in early R&D, accelerating their route from target ID to novel clinical candidate.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>Our community extends across the entire early R&D ecosystem, including biopharma, solution providers, start-ups, academics, and investors.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>Scientific & technical insights on the latest targets, platforms and processes impacting drug discovery & development.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Discovery & Development Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery%20and%20Development/BiomedGPT%20Adopting%20a%20Generalist%20Approach%20to%20Biomedical%20AI%20.png" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai">BiomedGPT: Adopting a Generalist Approach to Biomedical AI </a> </h3> <div class="resource-abstract"> <span class="resource-date">11/11/24 - </span> BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment">07/11/24 - The Application of RNAi Therapeutics for Cardiovascular Disease Treatment</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/ai-ml-advancements-in-drug-formulation-the-potential-of-self-driving-labs">16/10/24 - AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs </a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/discovery-development/resources/sponsored/case-studies/ardigen/advancing-drug-discovery-through-innovative-technologies-strategic-collaboration"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Advancing%20Drug%20Discovery%20Mock%20Up.png" class="sponsor-resource-bubble-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration </h3> <div class="resource-abstract"> A Concise Report Featuring Insights From The Prominent Thought Leaders Of Discovery & Automate 2024 </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Industry Spotlights & Insight Articles </div> <h1 class="heading"> Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope </h1> <div class="byline"> Edited by Tom Cohen | 02 May 2023 </div> <div class="abstract"> Positive phase III results propel innovative pherine nasal spray as potential game-changer for millions struggling with social anxiety disorder. Vistagen's novel mechanism of action sparks optimism after previous setback. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Tom-Industry-Spotlight-Template.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <p>Californian biopharmaceutical company Vistagen have announced positive results from their Phase III trial of a nasal spray designed to combat social anxiety.</p>   <p>The trial, PALISADE-2, tested efficacy, safety, and tolerability of the compound fasedienol (developmental name: PH94B) to treat patients with acute social anxiety disorder (SAD).</p>   <p>The results of the trial showed that the drug had achieved its primary endpoint: to exhibit a statistically significant improvement in stress during a public speaking challenge. Patients were assessed using the SUDS (subjective units of distress scale) metric, a self-reported 1-100 meter of subjective anxiety.</p>   <p><strong>RELATED:</strong></p>   <ul> <li><a href="https://oxfordglobal.com/discovery/resources/interview-with-valentina-mosienko-fellow-and-lecturer-in-neuroscience-university-of-bristol/" target="_blank" rel="noreferrer noopener">Interview with Valentina Mosienko, Fellow and Lecturer in Neuroscience, University of Bristol</a></li>   <li><a href="https://oxfordglobal.com/discovery/resources/gene-discovered-to-drive-anxiety-could-prove-an-effective-drug-target/" target="_blank" rel="noreferrer noopener">Gene Discovered to Drive Anxiety Could Prove an Effective Drug Target</a></li>   <li><a href="https://oxfordglobal.com/discovery/resources/prothena-and-evotec-score-major-deals-with-bristol-myers-squibb-for-neuroscience-breakthroughs/" target="_blank" rel="noreferrer noopener">Prothena and Evotec Score Major Deals with Bristol Myers Squibb for Neuroscience Breakthroughs</a></li> </ul>   <p></p>   <p>Another metric was used to test the medicine’s secondary endpoint: the CGI-I scale (clinical global impression - improvement), whereby a clinician assesses the improvement of a patient’s condition on a seven point scale. Again, fasedienol had a statistically significant improvement in this endpoint when compared to the placebo group.</p>   <p>Furthermore, the trial suggested the favourable tolerability and safety profile of the drug.</p>   <p>“We are thrilled that these compelling top-line results from the Phase 3 PALISADE-2 trial confirm what was seen in the Phase 2 studies in social anxiety disorder and highlight the potential for fasedienol, with its novel and unique proposed mechanism of action, to transform what is possible for more than 25 million people living with social anxiety in the U.S. and millions more affected worldwide,” stated Shawn Singh, Chief Executive Officer of Vistagen.</p>   <p>Fasedienol is the first drug candidate of its kind to exploit its particular mechanism of action. It’s a rapid-onset investigational pherine nasal spray that works by regulating the olfactory-amygdala neural circuits. Herein, it can attenuate the sympathetic autonomic nervous system (or, fight or flight response) without the need for systemic uptake or targeting neurological pathways in the CNS.</p>   <p>Singh said: “As a new class of medicines, our pherine nasal spray pipeline holds the potential to transform the treatment landscape across numerous therapeutic areas. At the head of that class, fasedienol’s potential, as demonstrated in this Phase 3 trial, sets the stage for the first fundamentally new class of medicine for individuals living with SAD in more than 20 years.”</p>   <p>The current therapies that are prescribed for anxiety are benzodiazepines, SSRIs, and beta-blockers, that regulate anxiety via systemic targeting of the CNS or SNS.</p>   <p>As a result of these positive results, the company saw its stock rise by 1,272% on Monday but has since levelled out around 13.00 USD.</p>   <p>This new trial and data appear after the failure of the drug in a previous phase III, trial PALISADE-1. Independent biostatisticians were brought in to assess the study of fasedienol and PALISADE-2, which led to talks with the FDA on the trial’s design.</p>   <p><em>Get your weekly dose of industry news?<a href="https://oxfordglobal.com/discovery/hub/?jsf=jet-engine&tax=resource_formats:322" target="_blank" rel="noreferrer noopener">here</a>?and keep up to date with the latest?‘Industry Spotlight’ posts.?For other Discovery content, please visit the?<a href="https://oxfordglobal.com/discovery/" target="_blank" rel="noreferrer noopener">Discovery Content Portal.</a></em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/FDA%20approves%20Bristol%20Myer%20Squibb%E2%80%99s%20first%20novel%20schizophrenia%20drug%20in%2035%20years.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <h4> Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years </h4> <div class="abstract"> According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults. </div> <div class="read-more"> <a href="/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Copy%20of%20Featured%20Image%20(6).png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <h4> Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments </h4> <div class="abstract"> Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles. </div> <div class="read-more"> <a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things Discovery & Development </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177049184347">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/discovery-development\/resources\/nasal-spray-shows-remarkable-efficacy-in-easing-social-anxiety-vistagens-fasedienol-promises-new-hope"]); _hsq.push(["setPageId", "hubdb-177028096592-7642658-170712574284"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177028096592-7642658-170712574284", "legacyPageId": "hubdb-177028096592-7642658-170712574284", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177028096592, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "877790c9-f7c8-46d1-8c6c-67636f731228", ticks: 1732347383389, page_id: 177028096592, dynamic_page_id: "hubdb-177028096592-7642658-170712574284", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177028096592-7642658-170712574284", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Nasal Spray Shows Remarkable Efficacy in Easing Social Anxiety: Vistagen's Fasedienol Promises New Hope